USFDA completes inspection of Lupin’s Vizag API manufacturing facility
18th Jan 2020

United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Vizag API manufacturing facility. The inspection was carried out between January 13, 2020 and January 17, 2020. The inspection for the API facility at Vizag closed with five 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.